It reduces intraocular pressure.
(Press Release) DURHAM, NC — Aerie Pharmaceuticals Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, announced that it has launched Rhopressa in the U.S.
Rhopressa is now in national and regional U.S. pharmaceutical distributors, and patients have access to Rhopressa through their local pharmacies across the nation.
"We are pleased to announce the availability in the United States of Rhopressa, the first new drug class in more than two decades for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension," said Vicente Anido, Jr., chairman and CEO. "Our national sales force is fully trained, deployed, and already providing product information and samples to physicians.
"Formulary contracts for commercial insurance coverage in 2018 and Medicare Part D program coverage beginning in 2019 are in the final stages of being executed. In addition, through the availability of a co-pay savings card program, all patients covered by commercial insurance will have immediate access to Rhopressa. Aerie has also proactively engaged the major e-prescribing platforms to ensure physicians are able to prescribe Rhopressa electronically for their patients. We look forward to providing additional details as part of our business update during our first-quarter 2018 financial results call scheduled for May 8, 2018."